{"brief_title": "Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis", "brief_summary": "The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.", "condition": ["Cystic Fibrosis"], "intervention_type": ["Drug"], "intervention_name": ["interferon gamma-1b"], "description": ["500 or 1000 mcg, inhalation, 3x per week"], "criteria": "Key inclusion criteria: - At least 12 years of age - Diagnosis of cystic fibrosis with mild to moderate pulmonary impairment - Must be receiving ongoing chronic treatment with TOBI (inhaled tobramycin) OR not receiving ongoing chronic treatment with TOBI and no use of TOBI or other inhaled antibiotic within 4 weeks prior to study drug administration\u00b7 - Other specific diagnostic indicators of CF and other factors must meet minimum requirements.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "pulmonary impairment", "mesh_term": ["Fibrosis", "Cystic Fibrosis", "Interferons", "Interferon-gamma"], "id": "NCT00043316"}